Enanta Pharmaceuticals (NASDAQ: ENTA) — Company Overview, News & Financial Data
Enanta Pharmaceuticals focuses on developing small molecule drugs for viral infections and liver diseases.
Enanta Pharmaceuticals
Enanta Pharmaceuticals (NASDAQ:ENTA) focuses on discovering, developing, and commercializing small molecule drugs for the treatment of viral infections and liver diseases. Specializing in creating treatments for respiratory syncytial virus, hepatitis B virus, and human metapneumovirus, Enanta is committed to addressing unmet medical needs. Their projects range from preclinical to phase 2 development, showcasing their comprehensive approach to tackling complex diseases. With objectives centered around innovation, patient health, and expanding their pipeline of therapeutic candidates, Enanta aims to be at the forefront of transformative treatment solutions.
Snapshot
Operations
Products and/or services of Enanta Pharmaceuticals
- Hepatitis C virus (HCV) regimens, offering a combination of direct-acting antivirals leading to high cure rates for infected patients.
- Respiratory syncytial virus (RSV) programs, focusing on developing treatments for severe RSV infections in pediatric and adult populations.
- Human Metapneumovirus and Parainfluenza Virus (hMPV/PIV) treatments, working on antiviral therapies for these lesser-known but impactful respiratory viruses.
- Hepatitis B virus (HBV) therapeutic solutions, developing treatments to manage and potentially cure chronic HBV infections.
- Coronavirus (COVID-19) research, exploring antiviral compounds to combat the SARS-CoV-2 virus and address the global pandemic.
Enanta Pharmaceuticals executive team
- Jay R. LulyPresident, CEO & Director
- Yat Sun OrChief Scientific Officer
- Scott T. RottinghausChief Medical Officer
- Harry R. Trout IIIVP of Finance & Interim Principal Financial Officer
- Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer
- Jennifer VieraExecutive Director of Investor Relations & Corporate Communications
- Matthew P. KowalskyChief Legal Officer & Corporate Secretary
- Nathaniel S. GardinerConsultant
- Tara Lynn KiefferChief Product Strategy Officer
- Brendan LuuChief Business Officer
Latest news about Enanta Pharmaceuticals
Key financials
Reported results for Enanta Pharmaceuticals, in USD.
- Market cap
- 302M
- Revenue (TTM)
- 65.3M
- P/E ratio
- —
- EPS (diluted, TTM)
- -2.4
- Dividend yield
- —
- Profit margin
- -96.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 65.3M | -85.3M | -81.9M | |
| 67.6M | -121.7M | -116M | |
| 79.2M | -137.2M | -133.8M | |
| 86.2M | -123.8M | -121.8M |